Fuda Cancer Hospital
| China | Turkey | Austria | |
| Tongue cancer surgery | from $12,500 | from $9,000 | from $35,000 |
| Partial Glossectomy | from $6,800 | from $5,500 | - |
| Halcyon | - | from $5,400 | - |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
The standard medical approach for tongue cancer in China follows a multimodal strategy centered on radical surgery and multidisciplinary care. Surgeons typically perform glossectomies supplemented by neck dissection for tumors exceeding 4mm in depth. Post-operative protocols often integrate radiation or chemoradiotherapy with traditional Chinese medicine to minimize toxicity.
Bookimed Expert Insight: While Western standards focus on surgery and radiation, top-tier Chinese institutions like Fuda Cancer Hospital distinguish themselves by offering 12 distinct minimally invasive options. These clinics frequently manage over 30,000 international patients by integrating vascular interventional therapy and microwave hyperthermia. This specialized expertise allows for complex treatment planning even in late-stage cases where traditional chemotherapy may be limited.
Patient Consensus: Patients note that even small tumors require extensive neck evaluations and detailed staging before treatment. They emphasize that speech and swallowing rehabilitation should be integrated into the surgical recovery plan from the start.
Minimally invasive and robotic surgeries are widely available for tongue cancer in China at tertiary medical centers. Surgeons utilize Transoral Robotic Surgery (TORS) and laser microsurgery to remove tumors through the mouth. These methods avoid large neck incisions and preserve speech and swallowing functions.
Bookimed Expert Insight: While major centers in Beijing and Shanghai lead in robotic volume, Fuda Cancer Hospital in Guangzhou offers a distinct specialized approach. They utilize over 10 types of minimally invasive therapies, including cryosurgery and NanoKnife, specifically for advanced or late-stage cancers. This provides a critical alternative for patients who may not be candidates for standard robotic resection but still require tissue-preserving interventions.
Patient Consensus: Patients emphasize that while robotic options sound appealing, the surgeon's ability to achieve clear margins and perform quality reconstruction is more important than the technology used. Many note that specialized speech and swallowing rehabilitation after surgery are the most vital factors for long-term recovery.
Tongue cancer surgery impacts speaking and swallowing, but the severity depends on the resection size. Most patients regain high speech clarity after a partial glossectomy within months. Total glossectomy requires alternative communication methods and significant dietary adjustments to ensure safe swallowing and nutrition.
Bookimed Expert Insight: Advanced centers like Fuda Cancer Hospital in Guangzhou combine surgical precision with minimally invasive therapies like cryosurgery or NanoKnife. This approach aims to preserve more healthy tissue compared to traditional wide-excision surgery. Minimizing healthy tissue loss is the most effective way to protect original tongue mobility and long-term speech naturalness.
Patient Consensus: Patients note that swallowing is often the hardest challenge early on, particularly with dry or crumbly foods. Many find that extra sauces and practicing speech out loud are the most helpful tools for regaining everyday independence.
Traditional Chinese Medicine cannot cure tongue cancer as a standalone treatment. There is no scientific evidence supporting it as a replacement for conventional oncology. Tongue cancer is aggressive and requires urgent surgery, radiation, or chemotherapy. Delaying these standard treatments significantly lowers survival rates.
Bookimed Expert Insight: While patients often seek TCM in China, leading JCI-accredited facilities like Fuda Cancer Hospital serve over 30,000 international patients by prioritizing minimally invasive Western techniques. They use NanoKnife and cryosurgery for tumor destruction. Use TCM only as a recovery aid, never as the primary tool for tumor eradication.
Patient Consensus: Patients warn that feeling better after using herbs does not mean the tumor is gone. They note that even small-looking lesions can be biologically aggressive and require immediate pathology and staging.
Major Chinese oncology centers provide English-speaking support through dedicated international departments. These specialized wings feature bilingual coordinators and medical reports issued in English. Facilities like the JCI-accredited Fuda Cancer Hospital in Guangzhou have treated over 30,000 international patients from 100 countries.
Bookimed Expert Insight: While many think a hospital's English website implies full bilingual care, the real bottleneck is the non-clinical workflow. Even at large centers, billing and pharmacy systems often remain Chinese-only. Choosing a facility with high international volume like Fuda Cancer Hospital typically ensures a smoother logistical experience.
Patient Consensus: Patients emphasize the need for written English communication rather than just verbal chats. They suggest confirming the availability of specific medical translators for surgical and rehabilitation discussions before starting treatment.
Remote follow-up care for tongue cancer patients treated in China is available through digital consultations and scan reviews. Specialist centers like Fuda Cancer Hospital utilize virtual triage to monitor wound healing. Stable patients often transition to a hybrid model combining local physical exams with remote oversight.
Bookimed Expert Insight: Success in remote follow-up with Chinese clinics relies heavily on documentation rather than live video calls. Since Fuda Cancer Hospital serves patients from 100+ countries, they prioritize reviewing clinical data over discs or cloud links. Ensure all pathology reports and PET/CT imaging are translated before departure to ensure seamless communication with your original medical team.
Patient Consensus: Patients note that while photos help, they shouldn't replace physical touch. Most recommend finding a local ENT doctor to handle physical checks while the Chinese team provides remote expertise.
China requires international patients to secure an S2 Private Affairs visa for long-term tongue cancer treatments like surgery or radiation. While some countries enjoy 30-day visa-free entry, oncology protocols often exceed this window. You must obtain an official medical invitation letter from the treating hospital.
Bookimed Expert Insight: Coordination is key because top oncology centers like Fuda Cancer Hospital in Guangzhou serve over 30,000 international patients. These high-volume hubs have dedicated departments to issue the specific red-seal invitations needed for visa approval. Securing this document before travel is vital as it justifies the stay duration to immigration officials.
Patient Consensus: Patients emphasize matching your visa category strictly to your medical purpose. They recommend requesting a flexible invitation that accounts for potential recovery delays and swallowing rehabilitation sessions.